257 related articles for article (PubMed ID: 25362986)
21. Identification of risk factors for catheter-related thrombosis in patients with totally implantable venous access ports in the forearm.
Goltz JP; Schmid JS; Ritter CO; Knödler P; Petritsch B; Kirchner J; Hahn D; Kickuth R
J Vasc Access; 2012; 13(1):79-85. PubMed ID: 21786241
[TBL] [Abstract][Full Text] [Related]
22. Totally Implantable Venous Access Port Systems: Implant Depth-based Complications in Breast Cancer Therapy - A Comparative Study.
Chen K; Beeraka NM; Gu Y; Li J; Sinelnikov M; Han N; Lu P
Curr Pharm Des; 2021; 27(46):4671-4676. PubMed ID: 34488584
[TBL] [Abstract][Full Text] [Related]
23. Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Haslik W; Hacker S; Felberbauer FX; Thallinger C; Bartsch R; Kornauth C; Deutschmann C; Mader RM
Eur J Surg Oncol; 2015 Mar; 41(3):378-85. PubMed ID: 25515823
[TBL] [Abstract][Full Text] [Related]
24. Fibrin sheath formation and chemotherapy extravasation: a case report.
Mayo DJ
Support Care Cancer; 1998 Jan; 6(1):51-6. PubMed ID: 9458537
[TBL] [Abstract][Full Text] [Related]
25. Power-injectable ports: safety during placement, therapeutic use, and contrast administration during computed tomography procedures.
Alexander MD; Morrison HL
J Vasc Access; 2012; 13(4):432-7. PubMed ID: 22610789
[TBL] [Abstract][Full Text] [Related]
26. The mystery of the occluded port that allowed blood withdrawal: is it safe to use standard needles to access ports? A case report and literature review.
Cataldo R; Costa F; Vitiello M; Brescia F; Proscia P; Falco C; Carassiti M
J Surg Oncol; 2014 Apr; 109(5):500-3. PubMed ID: 24310214
[TBL] [Abstract][Full Text] [Related]
27. Retained embolized fragment of totally implantable central venous catheter in right ventricle: it is really necessary to remove?
Tazzioli G; Gargaglia E; Vecchioni I; Papi S; Di Blasio P; Rossi R
J Vasc Access; 2015; 16(5):431-3. PubMed ID: 26109543
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy Extravasation Management: 21-Year Experience.
Onesti MG; Carella S; Fioramonti P; Scuderi N
Ann Plast Surg; 2017 Nov; 79(5):450-457. PubMed ID: 28906302
[TBL] [Abstract][Full Text] [Related]
29. Totally implantable venous access devices in children with medical complexity: preliminary data from a tertiary care hospital.
Geremia C; De Ioris MA; Crocoli A; Adorisio O; Scrocca R; Lombardi MH; Staccioli S; Stella P; Amendola P; Ciliento G; De Peppo F; Campana A
J Vasc Access; 2017 Sep; 18(5):426-429. PubMed ID: 28574141
[TBL] [Abstract][Full Text] [Related]
30. Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.
Subramaniam A; Kim KH; Bryant SA; Kimball KJ; Huh WK; Straughn JM; Estes JM; Alvarez RD
Gynecol Oncol; 2011 Oct; 123(1):54-7. PubMed ID: 21742372
[TBL] [Abstract][Full Text] [Related]
31. European Oncology Nursing Society extravasation guidelines.
Wengström Y; Margulies A;
Eur J Oncol Nurs; 2008 Sep; 12(4):357-61. PubMed ID: 18765210
[TBL] [Abstract][Full Text] [Related]
32. Common and uncommon complications of totally implantable central venous ports: a pictorial essay.
Perdikakis E; Kehagias E; Tsetis D
J Vasc Access; 2012; 13(3):345-50. PubMed ID: 22307469
[TBL] [Abstract][Full Text] [Related]
33. [Permanent venous access through a +portacath reservoir in patients receiving prolonged chemotherapy].
García H; Díaz R; Pablo Barés J; Nevah E; Fábrega JM
Rev Med Panama; 1994 Jan; 19(1):8-12. PubMed ID: 7938718
[TBL] [Abstract][Full Text] [Related]
34. Use of a totally implantable access port through the external jugular vein when the cephalic vein approach is not feasible.
Lin YC; Chu CH; Ou KW; Chan DC; Hsieh CB; Chen TW; Hsu HM; Yu JC
Ann Vasc Surg; 2011 Feb; 25(2):217-21. PubMed ID: 20926248
[TBL] [Abstract][Full Text] [Related]
35. Hypnosis as adjunct therapy to conscious sedation for venous access device implantation in breast cancer: A pilot study.
Sterkers N; Chabrol JL; De Troyer J; Bonijol D; Darmon JC; Donnez O
J Vasc Access; 2018 Jul; 19(4):382-386. PubMed ID: 29566587
[TBL] [Abstract][Full Text] [Related]
36. [A totally implantable permanent central venous access, long-term experience with subcutaneous infusion chambers].
Lorenz M; Hottenrott C; Seufert RM; Encke A
Langenbecks Arch Chir; 1988; 373(5):302-9. PubMed ID: 3077420
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy Extravasation: Establishing a National Benchmark for Incidence Among Cancer Centers.
Jackson-Rose J; Del Monte J; Groman A; Dial LS; Atwell L; Graham J; O'Neil Semler R; O'Sullivan M; Truini-Pittman L; Cunningham TA; Roman-Fischetti L; Costantinou E; Rimkus C; Banavage AJ; Dietz B; Colussi CJ; Catania K; Wasko M; Schreffler KA; West C; Siefert ML; Rice RD
Clin J Oncol Nurs; 2017 Aug; 21(4):438-445. PubMed ID: 28738039
[TBL] [Abstract][Full Text] [Related]
38. Reducing the risks of infiltration and extravasation.
Rosenthal K
Nursing; 2007; 37 Suppl Med():4-8. PubMed ID: 18163033
[No Abstract] [Full Text] [Related]
39. Intrathoracic extravasation of sclerosing agents associated with central venous catheters.
Watterson J; Heisel M; Cich JA; Priest JR
Am J Pediatr Hematol Oncol; 1988; 10(3):249-51. PubMed ID: 3177813
[TBL] [Abstract][Full Text] [Related]
40. Direct translumbar inferior vena cava ports for long-term central venous access in patients with cancer.
Butros SR; Walker TG; Salazar GM; Kalva SP; Oklu R; Wicky S; Ganguli S
J Vasc Interv Radiol; 2014 Apr; 25(4):556-60. PubMed ID: 24507994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
